Barclays’s Definium Therapeutics DFTX Stock Holding History

Barclays’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-68,900	Closed	-$3.24M	–	5602
2026 Q2	$3.24M	Buy	+68,900	New	+$1.7M	﹤0.01%	2080

Other funds holding DFTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Barclays's DFTX Position: Q3 2026 in Review

Barclays increased its Definium Therapeutics (DFTX) stake by 1,415% in Q3 2026, buying an estimated $30M and bringing the position to 761,867 shares worth $29M. The position accounts for 0.01% of the portfolio, ranked #1039.

Barclays first reported a position in DFTX in Q1 2022 and has held it in 19 quarters since. 253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

Barclays held 761,867 shares of Definium Therapeutics worth $29M as of Q3 2026.
Barclays bought 711,571 Definium Therapeutics shares in Q3 2026, an estimated $30M.
Definium Therapeutics made up 0.01% of Barclays's portfolio in Q3 2026, its #1039 holding.
Barclays first reported a position in Definium Therapeutics in Q1 2022 and has held it in 19 quarters since.
253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.